Cipla Limited
CIPLA
Rang in Aktien
#1816
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
Aktienkurs
$14.61
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$11.80B
Veränderung (1 Tag)
-0.12%
Veränderung (1 Jahr)
-21.66%
Land
IN
Handel Cipla Limited (CIPLA)
Kategorie
Healthcare
Gewinn für Cipla Limited (CIPLA)
Gewinn im Jun 2026 TTM: $499.57M
Laut den aktuellen Finanzberichten von Cipla Limited betragen die aktuellen Gewinne des Unternehmens $499.57M. Im Jahr 2024 erzielte das Unternehmen einen Gewinn von $683.63M, eine Steigerung gegenüber dem Gewinn im Jahr 2023, der $491.08M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Cipla Limited von 2004 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $499.57M | -37.16% |
| 2025 | $794.95M | 16.28% |
| 2024 | $683.63M | 39.21% |
| 2023 | $491.08M | 7.11% |
| 2022 | $458.50M | 2.41% |
| 2021 | $447.69M | 58.29% |
| 2020 | $282.83M | -4.75% |
| 2019 | $296.94M | 16.00% |
| 2018 | $255.98M | 36.61% |
| 2017 | $187.39M | -27.61% |
| 2016 | $258.87M | -0.84% |
| 2015 | $261.05M | -3.94% |
| 2014 | $271.76M | -29.32% |
| 2013 | $384.50M | 34.66% |
| 2012 | $285.52M | 9.46% |
| 2011 | $260.85M | -11.65% |
| 2010 | $295.26M | 67.39% |
| 2009 | $176.40M | -15.76% |
| 2008 | $209.41M | 12.35% |
| 2007 | $186.39M | 16.95% |
| 2006 | $159.38M | 35.23% |
| 2005 | $117.85M | 26.61% |
| 2004 | $93.09M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 253.21% |
IN
|
